ClinicalTrials.gg
CompletedNCT02725112Updated Jan 20, 2021

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

A Phase 1 interventional study of Pregabalin ER and Pregabalin ER in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-20.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2016, 10 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a Phase 1, randomized, open label, single dose, 6 treatment, 6 period, 6 sequence study in healthy adult volunteers. A total of 24 (4 in each treatment sequence) healthy male and female subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive will be enrolled. Subjects who discontinue from the study may be replaced at the Sponsor's discretion. Screening activities will be completed within approximately 28 days prior to Day 1 of Period 1. Subjects will be randomized to 1 of the 6 treatment sequences as described in Table 1 below. Each treatment sequence will consist of 6 periods with subjects receiving single doses of pregabalin ER 330 mg target release rate tablet, pregabalin ER 330 mg slow release rate tablet, pregabalin ER 330 mg fast release rate tablet, pregabalin IR 300 mg capsule, pregabalin ER 82.5 mg target release rate tablet, and pregabalin ER 330 mg aberrant fast release rate tablet formulations. All study treatments will be administered following a 600- 750 calorie, 30% fat evening meal.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female subjects and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead (ECG) or clinical laboratory tests. A 1:1 ratio of men to women is desirable, but it will not be considered a protocol deviation if this is not met.
  2. (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  3. Evidence of a personally signed and dated document.
  4. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. History of febrile illness within 5 days prior to the first dose of study product.
  3. Subjects with an estimated \<60 mL/min derived using the method of Crockcroft and Gault.1
  4. Any condition possibly affecting drug absorption.
  5. A positive urine drug screen.
  6. Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day.
  7. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of Screening.
  8. Treatment with an investigational drug within 30 days or 5 half lives preceding the first dose of study investigational product (whichever is longer).
  9. Screening supine blood pressure >= 140 mm Hg (systolic) or >= 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure is >= 140 mm Hg (systolic) or >= 90 mm Hg (diastolic), the blood pressure should be repeated 2 more times and the average of the 3 blood pressure values should be used to determine the subject's eligibility.
  10. Screening supine 12 lead demonstrating (time from ECG Q wave to the end of the T wave corresponding to electrical systole [QT] corrected for the heart rate) >450 msec or a QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization) >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the subject's eligibility.
  11. Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
  12. Use of prescription (other than oral, transdermal, intrauterine, implanted, or injected contraceptives or hormone replacement therapy) or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study medication.investigational product. Herbal supplements must be discontinued at least 28 days prior to the first dose of study medicationinvestigational product. As an exception, acetaminophen/paracetamol may be used at doses of greater than 1 g/day. Limited use of non prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case by case basis following approval by the Sponsor.
  13. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  14. History of sensitivity to pregabalin, gabapentin, or other alpha2 delta ligands.
  15. History of sensitivity to heparin or heparin induced thrombocytopenia.
  16. Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol.
  17. Previous participation in a study involving pregabalin.
  18. Subjects who are investigational site staff members directly involved in the study, their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees directly involved in the study.
  19. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Pregabalin ER- Target Release 330mg

    A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.

    Drug: Pregabalin ER

  • Experimental
    Pregabalin ER - Slow Release 330mg

    B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.

    Drug: Pregabalin ER

  • Experimental
    Pregabalin ER - Fast Release 330mg

    C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.

    Drug: Pregabalin ER

  • Experimental
    Pregabalin IR - 300mg

    D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.

    Drug: Pregabalin ER

  • Experimental
    Pregabalin ER - Target Release 82.5mg

    E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.

    Drug: Pregabalin ER

  • Experimental
    Pregabalin ER - Aberrant Fast 330mg

    F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.

    Drug: Pregabalin ER

Interventions

  • A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.

  • B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.

  • C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.

  • D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.

  • E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.

  • F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.

06

What researchers measure

Primary outcomes

  1. Cmax from time zero to infinity (AUCinf), when data permits, otherwise AUC from time zero to last quantifiable concentration (AUClast) of pregabalin ER 330 mg slow and fast release rate tablet formulations.

    To evaluate the relative bioavailability of pregabalin ER 330 mg slow and fast release rate tablet formulations administered immediately following an evening meal.

    Time frame: 10 week Study Duration

  2. AUC from time zero to infinity (AUCinf), when data permits, otherwise AUC from time zero to last quantifiable concentration (AUClast) of pregabalin ER 330 mg slow and fast release rate tablet formulations.

    To evaluate the relative bioavailability of pregabalin ER 330 mg slow and fast release rate tablet formulations administered immediately following an evening meal

    Time frame: 10 week Study Duration

Secondary outcomes

  1. Cmax of pregabalin.

    To evaluate the PK, safety and tolerability of single doses of pregabalin IR (300 mg) capsule formulation and pregabalin ER (82.5 and 330 mg) tablet formulations in healthy volunteers.

    Time frame: 10 week study duration

  2. Time to Cmax (Tmax) of pregabalin

    To evaluate the PK, safety and tolerability of single doses of pregabalin IR (300 mg) capsule formulation and pregabalin ER (82.5 and 330 mg) tablet formulations in healthy volunteers.

    Time frame: 10 week study duration

  3. Lag time (Tlag) of pregabalin

    To evaluate the PK, safety and tolerability of single doses of pregabalin IR (300 mg) capsule formulation and pregabalin ER (82.5 and 330 mg) tablet formulations in healthy volunteers.

    Time frame: 10 week study duration

  4. AUC of pregabalin

    To evaluate the PK, safety and tolerability of single doses of pregabalin IR (300 mg) capsule formulation and pregabalin ER (82.5 and 330 mg) tablet formulations in healthy volunteers.

    Time frame: 10 week study duration

  5. Terminal elimination half life (t½) of pregabalin

    To evaluate the PK, safety and tolerability of single doses of pregabalin IR (300 mg) capsule formulation and pregabalin ER (82.5 and 330 mg) tablet formulations in healthy volunteers.

    Time frame: 10 week study duration

  6. Safety endpoints include evaluation of AEs.

    To evaluate the PK, safety and tolerability of single doses of pregabalin IR (300 mg) capsule formulation and pregabalin ER (82.5 and 330 mg) tablet formulations in healthy volunteers.

    Time frame: 10 week study duration

07

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in May 2016, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2016
First posted
Mar 31, 2016
StartActual
Feb 12, 2016
Primary completionActual
May 22, 2016
CompletionActual
Jun 17, 2016
Last update
Jan 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02725112
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Feb 12, 2016
Primary completion
May 22, 2016
Completion
Jun 17, 2016
Last update
Jan 20, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion